

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

DISCLOSEABLE TRANSACTION
PURCHASE OF STRUCTURED DEPOSIT

PURCHASE OF STRUCTURED DEPOSIT

The Board announces that (i) on May 21, 2024, the Company entered into the CBHB Structured Deposit Agreement VII with CBHB, pursuant to which the Company agreed to purchase structured deposit in the principal amount of RMB60 million from CBHB; and (ii) on May 21, 2024, the Company entered into the CBHB Structured Deposit Agreement VIII with CBHB, pursuant to which the Company agreed to purchase structured deposit in the principal amount of RMB100 million from CBHB.

LISTING RULES IMPLICATIONS

As all of the applicable percentage ratios (as calculated under Rule 14.07 of the Listing Rules respectively) in respect of the transaction contemplated under the CBHB Structured Deposit Agreement VII and CBHB Structured Deposit Agreement VIII were below 5%, the purchase of structured deposit under each of the CBHB Structured Deposit Agreement VII and CBHB Structured Deposit Agreement VIII does not constitute a discloseable transaction of the Company under Chapter 14 of the Listing Rules on a standalone basis, respectively. As the CBHB Structured Deposit Agreement VII and CBHB Structured Deposit Agreement VIII were entered into with the same bank and the transactions thereunder are of similar nature as the transaction under each of the CBHB Structured Deposit Agreements I and VI (each of which remains outstanding as of the date of this announcement), the transactions contemplated under the CBHB Structured Deposit Agreements shall be aggregated pursuant to Rule 14.22 of the Listing Rules.

As the highest applicable percentage ratio in respect of the purchase of structure deposits under the CBHB Structured Deposit Agreements exceeds 5% but all of the applicable percentage ratios are less than 25%, the purchase of structured deposits under the CBHB Structured Deposit Agreements constitutes a discloseable transaction of the Company under Chapter 14 of the Listing Rules and is subject to the notification and announcement requirements under Chapter 14 of the Listing Rules.

INTRODUCTION

The Board announces that (i) on May 21, 2024, the Company entered into the CBHB Structured Deposit Agreement VII with CBHB, pursuant to which the Company agreed to purchase structured deposit in the principal amount of RMB60 million from CBHB; and (ii) on May 21, 2024, the Company entered into the CBHB Structured Deposit Agreement VIII with CBHB, pursuant to which the Company agreed to purchase structured deposit in the principal amount of RMB100 million from CBHB.

THE STRUCTURED DEPOSIT AGREEMENT

The principal terms of the CBHB Structured Deposit Agreement VII and CBHB Structured Deposit Agreement VIII are set out as follows:

Agreement	CBHB Structured Deposit Agreement VII	CBHB Structured Deposit Agreement VIII
Date of purchase	May 21, 2024	May 21, 2024
Parties	(a) The Company; and (b) CBHB	(a) The Company; and (b) CBHB
Name of the product	CBHB WBS241759 Structured Deposit* (渤海銀行 WBS241759 結構性存款)	CBHB WBS241760 Structured Deposit* (渤海銀行 WBS241760 結構性存款)
Type of return	Principal-guaranteed with variable return	Principal-guaranteed with variable return
Purchase amount	RMB60 million	RMB100 million
	<p>The consideration of such purchase was determined on the basis of arm's length commercial terms.</p> <p>The structured deposit was purchased with the funds redeemed upon maturity of the structured deposit purchased under the CBHB Structured Deposit Agreement V, without using the H Share IPO proceeds of the Company.</p>	<p>The consideration of such purchase was determined on the basis of arm's length commercial terms.</p> <p>The structured deposit was purchased with the internal funds of the Company, without using the H Share IPO proceeds of the Company.</p>
Term of deposit	From May 23, 2024 to June 24, 2024	From May 23, 2024 to August 26, 2024
Expected annualized rate of return	Expected rate of return = fixed return rate of 1.6% + 1.1% × N/M. 1.6% and 1.1% are both annualized rate of return. N is the actual number of days when the linked target is in the scope of the target range during the observation period, and M is the actual number of days of the observation period. The annualized fixed rate of return available to the Company is 1.6%, and the expected maximum annualized rate of return is 2.7%.	Expected rate of return = fixed return rate of 1.6% + 1.1% × N/M. 1.6% and 1.1% are both annualized rate of return. N is the actual number of days when the linked target is in the scope of the target range during the observation period, and M is the actual number of days of the observation period. The annualized fixed rate of return available to the Company is 1.6%, and the expected maximum annualized rate of return is 2.7%.

The linked target is the central parity rate of EUR/USD to be displayed on the “BFIX” page of the website of Bloomberg at 3:00 p.m. (Tokyo time) each day during the observation period. If there is no relevant data displayed on the “BFIX” page of the website of Bloomberg on a certain day, the linked target for that day will be the latest available central parity rate of EUR/USD displayed on the “BFIX” page of the website of Bloomberg at 3:00 p.m. (Tokyo time) before that day.

The observation period is from May 23, 2024 to June 20, 2024 (both days inclusive).

The target range is from the initial price of the linked target minus 0.045 to the initial price of the linked target plus 0.045 (boundaries of target inclusive).

The initial price of the linked target is the central parity rate of EUR/USD to be displayed on the “BFIX” page of the website of Bloomberg at 3:00 p.m. (Tokyo time) on the establishment date of the product, namely May 23, 2024.

The linked target is the central parity rate of EUR/USD to be displayed on the “BFIX” page of the website of Bloomberg at 3:00 p.m. (Tokyo time) each day during the observation period. If there is no relevant data displayed on the “BFIX” page of the website of Bloomberg on a certain day, the linked target for that day will be the latest available central parity rate of EUR/USD displayed on the “BFIX” page of the website of Bloomberg at 3:00 p.m. (Tokyo time) before that day.

The observation period is from May 23, 2024 to August 22, 2024 (both days inclusive).

The target range is from the initial price of the linked target minus 0.074 to the initial price of the linked target plus 0.074 (boundaries of target inclusive).

The initial price of the linked target is the central parity rate of EUR/USD to be displayed on the “BFIX” page of the website of Bloomberg at 3:00 p.m. (Tokyo time) on the establishment date of the product, namely May 23, 2024.

**Principle for
calculation of
return and interest**

Expected return = principal ×
expected annualized rate of return
× term of the product / 365

Expected return = principal ×
expected annualized rate of return
× term of the product / 365

Right of early termination	The Company has no right of early termination (redemption) for this product. CBHB has the right to early terminate this product if (i) the significant adjustments in national financial policies affect the normal operation of the product; (ii) extremely significant changes or emergency incidents occur in the market; and (iii) the financial instruments underlying this product have been terminated early, provided that it shall inform customers within two working days before the date of early termination and return principal and interests to customers within two working days after the date of early termination.	The Company has no right of early termination (redemption) for this product. CBHB has the right to early terminate this product if (i) the significant adjustments in national financial policies affect the normal operation of the product; (ii) extremely significant changes or emergency incidents occur in the market; and (iii) the financial instruments underlying this product have been terminated early, provided that it shall inform customers within two working days before the date of early termination and return principal and interests to customers within two working days after the date of early termination.
Payment of principal and return	The principal and the return of the product will be paid within two working days after the maturity date of the product.	The principal and the return of the product will be paid within two working days after the maturity date of the product.
Extension rights	In the event that financial instruments underlying the product fail to pay the principal and return in a timely manner, the term of the product will be extended.	In the event that financial instruments underlying the product fail to pay the principal and return in a timely manner, the term of the product will be extended.

INFORMATION ON THE PARTIES

The Company

The Company is dedicated to exploring best solutions to the prevention of infectious diseases through engaging in research and development, manufacturing and commercialization of high-quality vaccine products for human use worldwide.

CBHB

CBHB is a licensed bank in the PRC and a joint stock company established under the laws of the PRC, which provides corporate banking business, retail banking business, financial market business, financial technology business, assets and liabilities and financial management and other financial services in the PRC. Its H shares are listed on the Hong Kong Stock Exchange (stock code: 9668). To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, CBHB and its ultimate beneficial owners are parties independent of the Company and its connected persons as of the date of this announcement.

REASONS FOR AND BENEFITS OF THE PURCHASE OF STRUCTURED DEPOSIT

The Company is of the view that the reasonable and efficient use of temporary idle funds will enhance the overall capital gain of the Company, which is consistent with the core objectives of the Company to ensure capital safety and liquidity. The CBHB Structured Deposit Agreement VII and CBHB Structured Deposit Agreement VIII have low risks and higher returns as compared with ordinary fixed term deposits at commercial banks in the PRC.

The Directors consider that the terms of the CBHB Structured Deposit Agreement VII and CBHB Structured Deposit Agreement VIII and the transactions contemplated thereunder are fair and reasonable, on normal or better commercial terms and in the ordinary course of business of the Group, and are in the interests of the Company and its shareholders as a whole.

LISTING RULES IMPLICATIONS

As all of the applicable percentage ratios (as calculated under Rule 14.07 of the Listing Rules respectively) in respect of the transaction contemplated under the CBHB Structured Deposit Agreement VII and CBHB Structured Deposit Agreement VIII were below 5%, the purchase of structured deposit under each of the CBHB Structured Deposit Agreement VII and CBHB Structured Deposit Agreement VIII does not constitute a discloseable transaction of the Company under Chapter 14 of the Listing Rules on a standalone basis, respectively. As the CBHB Structured Deposit Agreement VII and CBHB Structured Deposit Agreement VIII were entered into with the same bank and the transactions thereunder are of similar nature as the transaction under each of the CBHB Structured Deposit Agreements I and VI (each of which remains outstanding as of the date of this announcement), the transactions contemplated under the CBHB Structured Deposit Agreements shall be aggregated pursuant to Rule 14.22 of the Listing Rules.

As the highest applicable percentage ratio in respect of the purchase of structure deposits under the CBHB Structured Deposit Agreements exceeds 5% but all of the applicable percentage ratios are less than 25%, the purchase of structured deposits under the CBHB Structured Deposit Agreements constitutes a discloseable transaction of the Company under Chapter 14 of the Listing Rules and is subject to the notification and announcement requirements under Chapter 14 of the Listing Rules.

DEFINITIONS

Unless the context otherwise requires, the capitalized terms used herein shall have the following meanings:

“Board”	the board of Directors
“CBHB”	CHINA BOHAI BANK CO., LTD. (渤海銀行股份有限公司), a joint stock company established on December 30, 2005 in the PRC with limited liability and whose H shares were listed on the Hong Kong Stock Exchange (Stock Code: 9668)
“CBHB Structured Deposit Agreements I and VI”	the structured deposit agreements entered into between the Company and CBHB dated January 11 and May 8, 2024 in relation to the purchase of structured deposit in the principal amount of RMB230 million and RMB200 million, respectively
“CBHB Structured Deposit Agreement V”	the structured deposit agreement entered into between the Company and CBHB dated April 11, 2024 in relation to the purchase of structured deposit in the principal amount of RMB60 million
“CBHB Structured Deposit Agreement VII”	the structured deposit agreement entered into between the Company and CBHB dated May 21, 2024 in relation to the purchase of structured deposit in the principal amount of RMB60 million
“CBHB Structured Deposit Agreement VIII”	the structured deposit agreement entered into between the Company and CBHB dated May 21, 2024 in relation to the purchase of structured deposit in the principal amount of RMB100 million
“CBHB Structured Deposit Agreements”	the CBHB Structured Deposit Agreements I and VI, CBHB Structured Deposit Agreement VII and CBHB Structured Deposit Agreement VIII
“Company”	CanSino Biologics Inc. (康希諾生物股份公司), a joint stock company incorporated in the PRC with limited liability on February 13, 2017, the H shares of which are listed on the Hong Kong Stock Exchange (stock code: 6185) and the A shares of which are listed on the Sci-Tech Innovation Board of the Shanghai Stock Exchange (stock code: 688185)
“connected person”	has the meaning ascribed to it in the Listing Rules
“Directors”	the director(s) of the Company
“EUR”	Euro, the lawful currency of the member states of the European Union
“Group”	the Company and its subsidiaries

“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Hong Kong Stock Exchange”	The Stock Exchange of Hong Kong Limited
“H Share IPO”	initial public offering of the H shares of the Company
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“PRC”	the People’s Republic of China, and for the purpose of this announcement only, excluding Hong Kong, the Macau Special Administrative Region and Taiwan
“RMB”	Renminbi, the lawful currency of the PRC
“USD”	US dollar, the lawful currency of the United States of America
“%”	per cent

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, May 21, 2024

As of the date of this announcement, the Board comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Ms. Nisa Bernice Wing-Yu LEUNG as a non-executive Director, and Mr. Shuifa GUI, Mr. Jianzhong LIU and Mr. Yiu Leung Andy CHEUNG as independent non-executive Directors.

* *For identification purpose only*